pragma.vision Technology observatory & strategic foresight

Verification register Bio, Health & Neuro

Readiness verdict

Teclistamab + daratumumab (Tecvayli combination)

A dated reading of what is claimed, reported, and independently verified in the current evidence.

As of
2026-08-20
Revision
1
Method
v1.3.0

Current reading

Readiness band and full integer triple

AI-assisted assembly · derived results

Readiness band

Mature

Primary summary from verified readiness

Confidence
75% · stale
Computed at
2026-08-20T10:54:10.346035+00:00
Claimed
90

Public ambition and stated capability

Reported
89

Observed practitioner reporting

Verified
83

Independently supported evidence

Gap
+7

Claimed leads verified

Evidence strength Strong

Decision

What the current evidence supports

Human editorial judgment · 2026-08-20

Adopt with guardrails

Why
Practice-changing Phase 3 data (first positive Phase 3 of a bispecific in myeloma) and full FDA approval put this at high maturity — but the infection/fatal-AE profile mandates real guardrails, and it is an approved drug rather than a speculative platform tech.
Next
Use as a reference exemplar of a mature, FDA-approved bispecific combination; apply infection-prophylaxis guardrails (IVIG + antimicrobial prophylaxis) per the MajesTEC-3 protocol amendment that reduced infection incidence.

Constraints

Blockers

No named blocker is present in the current public projection.

Evidence summary

Derived counts

AI-assisted assembly

Total
12
Tier 1
0
Tier 2
4
Tier 3
8
Supports
6
Contradicts
2
Context
4
Latest observed
2026-03-05

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Revisions

Initial public reading

  1. 2026-07-19 Reading moved from mature to mature.

Your opinion

Tell us anything.

What works, what doesn't, what's missing — especially about our watches, lenses, and the register itself. Anonymous is fine; leave an email if you'd like a reply.